Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 USD | +0.83% | +6.70% | -40.28% |
04-01 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
04-01 | Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans | MT |
Sales 2021 | 1.42 1.94 | Sales 2022 | 0.7 0.96 | Capitalization | 103M 141M |
---|---|---|---|---|---|
Net income 2021 | -63M -86.1M | Net income 2022 | -58M -79.26M | EV / Sales 2021 | 297,232,229 x |
Net cash position 2021 | 17.36M 23.73M | Net Debt 2022 | 14.82M 20.25M | EV / Sales 2022 | 168,485,877 x |
P/E ratio 2021 |
-6.51
x | P/E ratio 2022 |
-1.61
x | Employees | 61 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.62% |
Latest transcript on Pulse Biosciences, Inc.
1 day | +0.83% | ||
1 week | +6.70% | ||
Current month | -16.08% | ||
1 month | -8.52% | ||
3 months | -21.24% | ||
6 months | +65.74% | ||
Current year | -40.28% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Danahy
CEO | Chief Executive Officer | 54 | 22-02-13 |
Chief Tech/Sci/R&D Officer | - | 23-05-02 | |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CHM | Chairman | 79 | 17-11-01 |
Director/Board Member | 46 | 17-11-01 | |
Darrin Uecker
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-09-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.36% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 7.309 | +1.66% | 4 377 |
24-04-26 | 7.19 | +7.47% | 71,325 |
24-04-25 | 6.69 | -2.48% | 117,307 |
24-04-24 | 6.86 | 0.00% | 129,156 |
24-04-23 | 6.86 | +0.15% | 124,448 |
Delayed Quote Nasdaq, April 29, 2024 at 09:36 am
More quotes1st Jan change | Capi. | |
---|---|---|
-40.28% | 397M | |
+8.26% | 219B | |
+7.24% | 183B | |
+11.73% | 133B | |
+26.15% | 108B | |
+1.71% | 63.06B | |
+13.18% | 52.02B | |
-0.62% | 48.2B | |
+0.31% | 40.37B | |
+12.74% | 39.35B |
- Stock Market
- Equities
- PLSE Stock